MORPHINE STRENGTH NON-ADDICTIVE PAIN TREATMENT Trademark

Trademark Overview

On Wednesday, March 2, 2016, a trademark application was filed for MORPHINE STRENGTH NON-ADDICTIVE PAIN TREATMENT with the United States Patent and Trademark Office. The USPTO has given the MORPHINE STRENGTH NON-ADDICTIVE PAIN TREATMENT trademark a serial number of 86926766. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Tuesday, October 16, 2018. This trademark is owned by PixarBio Corporation. The MORPHINE STRENGTH NON-ADDICTIVE PAIN TREATMENT trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Drug, agent and cell delivery system comprised of a range of biomaterial formulations for neurological use, namely, a biodegradable synthetic polymer in the form of particles for structured drug release of active pharmaceutical ingredients; drug, agent and cell delivery system comprised of a range of biomaterial formulations for neurological use, namely, implants composed of biodegradable materials in the nature of living tissue

Drug, agent and cell delivery system comprised of a range of biomaterial formulations for neurological use, namely, implants composed of synthetic biodegradable materials
morphine strength non-addictive pain treatment

General Information

Serial Number86926766
Word MarkMORPHINE STRENGTH NON-ADDICTIVE PAIN TREATMENT
Filing DateWednesday, March 2, 2016
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateTuesday, October 16, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesDrug, agent and cell delivery system comprised of a range of biomaterial formulations for neurological use, namely, a biodegradable synthetic polymer in the form of particles for structured drug release of active pharmaceutical ingredients; drug, agent and cell delivery system comprised of a range of biomaterial formulations for neurological use, namely, implants composed of biodegradable materials in the nature of living tissue
Goods and ServicesDrug, agent and cell delivery system comprised of a range of biomaterial formulations for neurological use, namely, implants composed of synthetic biodegradable materials

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 7, 2016
Primary Code005
First Use Anywhere DateMonday, March 28, 2016
First Use In Commerce DateMonday, March 28, 2016
International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateMonday, March 7, 2016
Primary Code010
First Use Anywhere DateMonday, March 28, 2016
First Use In Commerce DateMonday, March 28, 2016

Trademark Owner History

Party NamePixarBio Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSalem, NH 03079

Trademark Events

Event DateEvent Description
Wednesday, October 17, 2018ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Tuesday, October 16, 2018ABANDONMENT - AFTER EX PARTE APPEAL
Tuesday, October 16, 2018EXPARTE APPEAL TERMINATED
Tuesday, October 16, 2018EXPARTE APPEAL DSMSED - FAILURE TO FILE BRIEF
Thursday, May 24, 2018NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Thursday, May 24, 2018ACTION DENYING REQ FOR RECON E-MAILED
Thursday, May 24, 2018SUBSEQUENT FINAL REFUSAL WRITTEN
Thursday, May 3, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 2, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 2, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, November 2, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 2, 2017NON-FINAL ACTION E-MAILED
Thursday, November 2, 2017NON-FINAL ACTION WRITTEN
Thursday, October 12, 2017JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, September 7, 2017APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, September 7, 2017TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, July 28, 2017NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Friday, July 28, 2017ACTION DENYING REQ FOR RECON E-MAILED
Friday, July 28, 2017ACTION CONTINUING FINAL - COMPLETED
Wednesday, July 12, 2017TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, July 12, 2017EX PARTE APPEAL-INSTITUTED
Wednesday, July 12, 2017JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, July 12, 2017EXPARTE APPEAL RECEIVED AT TTAB
Thursday, January 12, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, January 12, 2017FINAL REFUSAL E-MAILED
Thursday, January 12, 2017FINAL REFUSAL WRITTEN
Thursday, December 22, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 21, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 21, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 6, 2016ASSIGNED TO EXAMINER
Tuesday, November 15, 2016ASSIGNED TO EXAMINER
Tuesday, June 21, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 21, 2016NON-FINAL ACTION E-MAILED
Tuesday, June 21, 2016NON-FINAL ACTION WRITTEN
Thursday, June 16, 2016NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Wednesday, June 15, 2016USE AMENDMENT ACCEPTED
Tuesday, June 14, 2016ASSIGNED TO EXAMINER
Saturday, April 16, 2016AMENDMENT TO USE PROCESSING COMPLETE
Saturday, April 16, 2016USE AMENDMENT FILED
Friday, April 15, 2016TEAS AMENDMENT OF USE RECEIVED
Monday, March 7, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, March 5, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

treatment pain addictive strength morphine drug biomaterial formulations biodegradable range namely neurological cell comprised delivery